Plasma Therapy: Market Segments: By Type (Pure PRP, Leucocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin); By Source (Autologous and Allogenic); By Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury and Others); By End User (Hospitals & Clinics and Research Institutions) and Region – Global Analysis of Market Size, Share & Trends for 2014– 2020 and Forecasts to 2030
Plasma Therapy: Market Segments: By Type (Pure PRP, Leucocyte-Rich PRP, Pure Platelet-Rich Fibrin and Leukocyte-Rich Fibrin); By Source (Autologous and Allogenic); By Application (Orthopedics, Dermatology, Dental, Cardiac Muscle Injury, Nerve Injury and Others); By End User (Hospitals & Clinics and Research Institutions) and Region – Global Analysis of Market Size, Share & Trends for 2014– 2020 and Forecasts to 2030Product Overview
Plasma is the main component of blood which accounts for more than half (about 55%) of its overall content. Water, salts, and enzymes are transported by plasma. Plasma's primary function is to carry nutrients, hormones, and proteins to the areas of the body that need them. Plasma therapy is a medical technique that uses a healed patient's blood to produce antibodies against certain individuals that are infected.Market Highlights
Global Plasma Therapy is expected to project a notable CAGR of 12.74 % in 2030.
Global Plasma Therapy to surpass USD 744.18 million by 2030 from USD 195.9 million in 2020 at a CAGR of 12.74 % in the coming years, i.e., 2020-30. Growing incidences of sports injuries are driving the growth of the global plasma therapy market. Global Plasma Therapy: Segments
Pure PRP segment to grow with the highest CAGR during 2020-30
Global Plasma Therapy is segmented by type into Pure PRP, Leucocyte-Rich PRP, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Fibrin. Pure PRP, the segment held the largest market share of XX.X% in the year 2019 because of its effective result in treatment. Increased health care funding and increased use of PRP in hospitals and other clinics are propelling the growth of the market. Due to increased use and antimicrobial effects, the Pure Platelet-Rich segment is also expected to have healthy growth.Market Dynamics
Drivers
Rising incidences of osteoarthritis
Increasing incidences of osteoarthritis are expected to drive the plasma therapy market in the near future. A type of plasma therapy, platelet-rich plasma (PRP), is considered a safe and effective treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by reducing inflammation and slowing the progression of osteoarthritis. This therapy is a simple, minimally invasive technique that can be performed in primary care to treat knee joint osteoarthritis.Restraint
High cost associated with plasma therapy
High price of plasma therapy is anticipated to restrict the market growth. The market is limited by the cost of extraction of plasma from blood and storage of extracted plasma. The procedure of separating plasma and blood cells from the blood is called Plasmapheresis. The cost of Plasmapheresis is high which impedes many patients to access the treatment.
Global Plasma Therapy:
Key Players
Arthrex, Inc.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bio Products Laboratory Ltd.
Takeda Pharmaceutical Company Limited.
Biotest AG.
Cambryn Biologics
China Biologic Products Holdings, Inc.
CSL Limited
DePuy Synthes
Grifols, S.A.
Kedrion S.p.A.
Octapharma, Regen Lab SA
Other Prominent Players
Global Plasma Therapy: Regions
Global Plasma Therapy is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Plasma Therapy in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Plasma Therapy owing to rising healthcare expenditure and the rising awareness about plasma donation among consumers. Besides, the growing occurrence of orthopedic and sports injuries and the rising geriatric population in the region is predicted to proliferate the plasma therapy market.
Plasma is the main component of blood which accounts for more than half (about 55%) of its overall content. Water, salts, and enzymes are transported by plasma. Plasma's primary function is to carry nutrients, hormones, and proteins to the areas of the body that need them. Plasma therapy is a medical technique that uses a healed patient's blood to produce antibodies against certain individuals that are infected.Market Highlights
Global Plasma Therapy is expected to project a notable CAGR of 12.74 % in 2030.
Global Plasma Therapy to surpass USD 744.18 million by 2030 from USD 195.9 million in 2020 at a CAGR of 12.74 % in the coming years, i.e., 2020-30. Growing incidences of sports injuries are driving the growth of the global plasma therapy market. Global Plasma Therapy: Segments
Pure PRP segment to grow with the highest CAGR during 2020-30
Global Plasma Therapy is segmented by type into Pure PRP, Leucocyte-Rich PRP, Pure Platelet-Rich Fibrin, and Leukocyte-Rich Fibrin. Pure PRP, the segment held the largest market share of XX.X% in the year 2019 because of its effective result in treatment. Increased health care funding and increased use of PRP in hospitals and other clinics are propelling the growth of the market. Due to increased use and antimicrobial effects, the Pure Platelet-Rich segment is also expected to have healthy growth.Market Dynamics
Drivers
Rising incidences of osteoarthritis
Increasing incidences of osteoarthritis are expected to drive the plasma therapy market in the near future. A type of plasma therapy, platelet-rich plasma (PRP), is considered a safe and effective treatment for osteoarthritis. Platelet-rich plasma (PRP) is a concentrated autologous blood growth factor that is injected into the joint to provide symptomatic relief by reducing inflammation and slowing the progression of osteoarthritis. This therapy is a simple, minimally invasive technique that can be performed in primary care to treat knee joint osteoarthritis.Restraint
High cost associated with plasma therapy
High price of plasma therapy is anticipated to restrict the market growth. The market is limited by the cost of extraction of plasma from blood and storage of extracted plasma. The procedure of separating plasma and blood cells from the blood is called Plasmapheresis. The cost of Plasmapheresis is high which impedes many patients to access the treatment.
Global Plasma Therapy:
Key Players
Arthrex, Inc.
Company Overview, Business Strategy, Key Product Offerings, Financial Performance, Key Performance Indicators, Risk Analysis, Recent Development, Regional Presence, SWOT Analysis
Bio Products Laboratory Ltd.
Takeda Pharmaceutical Company Limited.
Biotest AG.
Cambryn Biologics
China Biologic Products Holdings, Inc.
CSL Limited
DePuy Synthes
Grifols, S.A.
Kedrion S.p.A.
Octapharma, Regen Lab SA
Other Prominent Players
Global Plasma Therapy: Regions
Global Plasma Therapy is segmented based on regional analysis into five major regions. These include North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Global Plasma Therapy in North America held the largest market share of XX.X% in the year 2019. North America will continue to dominate the global Plasma Therapy owing to rising healthcare expenditure and the rising awareness about plasma donation among consumers. Besides, the growing occurrence of orthopedic and sports injuries and the rising geriatric population in the region is predicted to proliferate the plasma therapy market.
1. EXECUTIVE SUMMARY
2. GLOBAL PLASMA THERAPY MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL PLASMA THERAPY MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL PLASMA THERAPY MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL PLASMA THERAPY MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Type: Market Share (2020-2030F)
12.2.1. Pure PRP, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Leucocyte-Rich PRP, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Pure Platelet-Rich Fibrin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Leukocyte-Rich Fibrin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Source: Market Share (2020-2030F)
12.3.1. Autologous, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Allogenic, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Application: Market Share (2020-2030F)
12.4.1. Orthopedics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Dermatology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Dental, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.4. Cardiac Muscle Injury, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.5. Nerve Injury, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By End-Users: Market Share (2020-2030F)
13. HEALTHCARE & CLINICS, BY VALUE (USD MILLION) 2020-2030F; Y-O-Y GROWTH (%) 2021-2030F
14. RESEARCH INSTITUTIONS, BY VALUE (USD MILLION) 2020-2030F; Y-O-Y GROWTH (%) 2021-2030F
15. COMPANY PROFILE
16. ARTHREX, INC.
16.1. Company Overview
16.2. Company Total Revenue (Financials)
16.3. Market Potential
16.4. Global Presence
16.5. Key Performance Indicators
16.6. SWOT Analysis
16.7. Product Launch
17. BIO PRODUCTS LABORATORY LTD.
18. TAKEDA PHARMACEUTICAL COMPANY LIMITED.
19. BIOTEST AG.
20. CAMBRYN BIOLOGICS
21. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
22. CSL LIMITED
23. DEPUY SYNTHES
24. GRIFOLS, S.A.
25. KEDRION S.P. A.
26. OCTAPHARMA, REGEN LAB SA
27. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
2. GLOBAL PLASMA THERAPY MARKET
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. RESEARCH METHODOLOGY
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. AVERAGE PRICING ANALYSIS
5. MACRO-ECONOMIC INDICATORS
6. MARKET DYNAMICS
6.1. Growth Drivers
6.2. Restraints
6.3. Opportunity
6.4. Trends
7. CORRELATION & REGRESSION ANALYSIS
7.1. Correlation Matrix
7.2. Regression Matrix
8. RECENT DEVELOPMENT, POLICIES & REGULATORY LANDSCAPE
9. RISK ANALYSIS
9.1. Demand Risk Analysis
9.2. Supply Risk Analysis
10. GLOBAL PLASMA THERAPY MARKET ANALYSIS
10.1. Porters Five Forces
10.1.1. Threat of New Entrants
10.1.2. Bargaining Power of Suppliers
10.1.3. Threat of Substitutes
10.1.4. Rivalry
10.2. PEST Analysis
10.2.1. Political
10.2.2. Economic
10.2.3. Social
10.2.4. Technological
11. GLOBAL PLASMA THERAPY MARKET
11.1. Market Size & forecast, 2020A-2030F
11.1.1. By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
11.1.2. By Volume (Million Units) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12. GLOBAL PLASMA THERAPY MARKET: MARKET SEGMENTATION
12.1. By Regions
12.1.1. North America:(U.S. and Canada), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.2. Latin America: (Brazil, Mexico, Argentina, Rest of Latin America), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.3. Europe: (Germany, UK, France, Italy, Spain, BENELUX, NORDIC, Hungary, Poland, Turkey, Russia, Rest of Europe), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.4. Asia-Pacific: (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia Pacific), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.1.5. Middle East and Africa: (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa), By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2. By Type: Market Share (2020-2030F)
12.2.1. Pure PRP, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.2. Leucocyte-Rich PRP, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.3. Pure Platelet-Rich Fibrin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.2.4. Leukocyte-Rich Fibrin, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3. By Source: Market Share (2020-2030F)
12.3.1. Autologous, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.3.2. Allogenic, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4. By Application: Market Share (2020-2030F)
12.4.1. Orthopedics, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.2. Dermatology, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.3. Dental, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.4. Cardiac Muscle Injury, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030
12.4.5. Nerve Injury, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.4.6. Others, By Value (USD Million) 2020-2030F; Y-o-Y Growth (%) 2021-2030F
12.5. By End-Users: Market Share (2020-2030F)
13. HEALTHCARE & CLINICS, BY VALUE (USD MILLION) 2020-2030F; Y-O-Y GROWTH (%) 2021-2030F
14. RESEARCH INSTITUTIONS, BY VALUE (USD MILLION) 2020-2030F; Y-O-Y GROWTH (%) 2021-2030F
15. COMPANY PROFILE
16. ARTHREX, INC.
16.1. Company Overview
16.2. Company Total Revenue (Financials)
16.3. Market Potential
16.4. Global Presence
16.5. Key Performance Indicators
16.6. SWOT Analysis
16.7. Product Launch
17. BIO PRODUCTS LABORATORY LTD.
18. TAKEDA PHARMACEUTICAL COMPANY LIMITED.
19. BIOTEST AG.
20. CAMBRYN BIOLOGICS
21. CHINA BIOLOGIC PRODUCTS HOLDINGS, INC.
22. CSL LIMITED
23. DEPUY SYNTHES
24. GRIFOLS, S.A.
25. KEDRION S.P. A.
26. OCTAPHARMA, REGEN LAB SA
27. OTHER PROMINENT PLAYERS
Consultant Recommendation
**The above-given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.
